{
  "docId": "019de070-fbaf-759b-8cbd-9f18172b1352",
  "docSlug": "7d8ead18d80cb869cda17e33a74aeb0b",
  "documentTitle": "BioNTech | Results Presentation Deck | 30 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 30,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide outlines a clinical trial structure (Phase 1/2a) for a CAR-T therapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-fbaf-759b-8cbd-9f18172b1352/19",
  "deckHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352",
  "deckJsonHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352.json",
  "deckAnchorHref": "/decks/019de070-fbaf-759b-8cbd-9f18172b1352#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.82,
        "x": 0.09,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Clinical trial flow from BNT211 patient selection to Part 1/2 dose escalation, RP2D determination, and Part 3 expansion cohorts.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f8e326b-4149-4839-8361-9268d2f3d7c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.35,
        "x": 0.5,
        "y": 0.68
      },
      "kind": "list",
      "text": "Evaluation of safety and tolerability; Ongoing Phase 1/2a study; Monotherapy dose level 1 completed (3 patients)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97d75ff0-be20-4e03-91e7-9bcd2dcc269f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.12,
        "y": 0.71
      },
      "kind": "paragraph",
      "text": "An open-label Phase 1/2a study of BNT211 in patients with advanced solid tumors",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "894990a5-1004-43d2-bab3-e6f6d5d39c9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.68,
        "x": 0.07,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor engineered T cells; RP2D, recommended Phase 2 dose; NOS, not otherwise specified; NCT04503278",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73ccc720-7dd9-4d10-82e0-b41c23098ecd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "BNT211: Next Generation CAR-T Therapy in Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0662ce47-cf34-4905-be8e-6438459e8c5c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 17,
      "beatId": "b630b8e9-6492-4b4d-a542-b4aa7c3b986e",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck concludes with financial results, global footprint, and pipeline milestones",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "3e964042-540f-49d8-932e-54e5cecf05d0",
      "evidence": "The deck highlights the company's progress on COVID-19 vaccine deliveries and revenue growth",
      "position": 1,
      "objective": "The consequences of not acting on COVID-19 vaccine strategy",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.5,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}